Process monitoring of an HIV Treatment as Prevention program in British Columbia, Canada

Journal of Acquired Immune Deficiency Syndromes

Volumn 67, Issue 3, 2014, Pages e94-e109

  Lourenço, Lillian ^a   Lima, Viviane D ^a,b   Heath, Kate ^a   Nosyk, Bohdan ^a,c   Gilbert, Mark ^d   Colley, Guillaume ^a   Consolacion, Theodora ^d   Barrios, Rolando ^e   Hogg, Robert ^a,c   Krajden, Mel ^d   Konrad, Stephanie ^f   Murti, Michelle ^f   Nelson, Joanne ^g   May Hadford, Jennifer ^h   Haggerstone, James ⁱ   Pick, Neora ^j   Gustafson, Reka ^e   Rusch, Melanie ^k   Day, Irene ^a   Montaner, Julio S G ^a,b  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c SIMON FRASER UNIVERSITY   (Canada)

^d BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^e VANCOUVER COASTAL HEALTH   (Canada)

^f FRASER HEALTH AUTHORITY   (Canada)

^g First Nations Health Authority   (Canada)

^h Interior Health Authority   (Canada)

ⁱ Northern Health Authority   (Canada)

^j PROVINCIAL HEALTH SERVICES AUTHORITY   (Canada)

^k VANCOUVER ISLAND HEALTH AUTHORITY   (Canada)

more..

Author keywords

Canada; HIV; Monitoring; TasP; Treatment as prevention

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; INDICATOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; CANADA; CD4 LYMPHOCYTE COUNT; CONFERENCE PAPER; DEMOGRAPHY; DISEASE CONTROL; DISEASE COURSE; DRUG RESISTANCE; FEMALE; GENOTYPE; GOLD STANDARD; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PRIORITY JOURNAL; PROCESS MONITORING; TREATMENT PLANNING; BRITISH COLUMBIA; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; HIV INFECTIONS; IMMUNOLOGY; PROGRAM EVALUATION; STANDARDS; VIROLOGY; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRITISH COLUMBIA; CD4 LYMPHOCYTE COUNT; EVIDENCE-BASED MEDICINE; HIV INFECTIONS; HUMANS; PROGRAM EVALUATION; QUALITY INDICATORS, HEALTH CARE; VIRAL LOAD;

EID: 84927728149     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000293     Document Type: Conference Paper

References (57)

1. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA. 1996;276:146-154.
2. The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372:293-299.
3. Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;8:e81355.
4. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308:387-402.
5. Organization WH. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. 2013. ISBN: 978 92 4 150572 7.
6. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services; 2013. Available at http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed March 1, 2014.
7. Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376:532-539.
8. Lima VD, Hogg RS, Montaner JS. Expanding HAART treatment to all currently eligible individuals under the 2008 IAS-USA Guidelines in British Columbia, Canada. PLoS One. 2010;5:e10991.
9. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48-57.
10. Fang CT, Hsu HM, Twu SJ, et al. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis. 2004;190:879-885.
11. Wood E, Kerr T, Marshall BD, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ. 2009;338:b1649.
12. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One. 2010;5:e11068.
13. Jia Z, Mao Y, Zhang F, et al. Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003-11): a national observational cohort study. Lancet. 2013;382:1195-1203.
14. Hogg RS, Heath K, Lima VD, et al. Disparities in the burden of HIV/AIDS in Canada. PLoS One. 2012;7:e47260.
15. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
16. Johnston KM, Levy AR, Lima VD, et al. Expanding access to HAART: a cost-effective approach for treating and preventing HIV. AIDS. 2010; 24:1929-1935.
17. Granich R, Kahn JG, Bennett R, et al. Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050. PLoS One. 2012;7:e30216.
18. Walensky RP, Ross EL, Kumarasamy N, et al. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med. 2013; 369:1715-1725.
19. Sidibé Michel. Letter to Partners. Geneva, Switzerland: UNAIDS; 2010.
20. Doherty M, Ford N, Vitoria M, et al. The 2013 WHO guidelines for antiretroviral therapy: evidence-based recommendations to face new epidemic realities. Curr Opin HIV AIDS. 2013;8:528-534.
21. Cheever LW. Engaging HIV-infected patients in care: their lives depend on it. Clin Infect Dis. 2007;44:1500-1502.
22. Mugavero MJ, Norton WE, Saag MS. Health care system and policy factors influencing engagement in HIV medical care: piecing together the fragments of a fractured health care delivery system. Clin Infect Dis. 2011;52(suppl 2):S238-S246.
23. World Health Organization. Programmatic Update Antiretroviral Treatment as Prevention of HIV and TB. Geneva: World Health Organization; 2012.
24. Gardner EM, McLees MP, Steiner JF, et al. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52:793-800.
25. Hallett TB, Eaton JW. A side door into care cascade for HIV-infected patients? J Acquir Immune Defic Syndr. 2013;63(suppl 2):S228-S232.
26. Montaner JS, Lima VD, Harrigan PR, et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the "HIV treatment as prevention" experience in a Canadian setting. PLoS One. 2014;9:e87872.
27. Nosyk B, Colley G, Yip B, et al. Application and validation of casefinding algorithms for identifying individuals with human immunodeficiency virus from administrative data in British Columbia, Canada. PLoS One. 2013;8:e54416.
28. Heath K, Samji H, Nosyk B, et al; on behalf of the STOP HIV/AIDS Study Group. Cohort Profile: Seek and Treat for the Optimal Prevention of HIV/AIDS in British Columbia (STOP HIV/AIDS BC). Int J Epidemiol. 2014;43:1073-1081.
29. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286:2568-2577.
30. Centers for Disease Control and Prevention. Framework for program evaluation in public health. MMWR. 1999;48(No. RR-11):1-40.
31. Health BCMo. From Hope to Health Towards an AIDS-Free Generation. Vancouver, Canada: Health BCMo; 2012.
32. UNAIDS. Indicator Standards: Operational Guidelines for Selecting Indicators for the HIV Response. Geneva: UNAIDS; 2010.
33. Institute of Medicine CoUPMtICH. Improving Health in the Community: A Role for Performance Monitoring. Washington, DC: National Academy Press; 1997.
34. USAID MD. HIV/AIDS Survey Indicators Database. Available at: http://hivdata.measuredhs.com/ind-tbl.cfm. Accessed January 20, 2014.
35. US Department of Health and Human Services health Resources and Services Administration HIV/AIDS Programs. HIV/AIDS Bureau (HAB) HIV Performance Measures. 2013. Available at: http://hab.hrsa.gov/deliverhivaidscare/ habperformmeasures.html. Accessed February 15, 2014.
36. UNAIDS. Global AIDS Response Progress Reporting. 2013. Available at: http://www.indicatorregistry.org/.
37. UNAIDS. A Framework for Monitoring and Evaluating HIV Prevention Programmes for Most-at-Risk Populations. Geneva, Switzerland: UNAIDS; 2008.
38. UNAIDS UaW. Global AIDS Response Progress Reporting: Construction of Core Indicators for Monitoring the 2011 UN Political Declaration on HIV/AIDS. Geneva, Switzerland; 2013.
39. Institute of Medicine. Monitoring HIV Care in the United States: Indicators and Data Systems. Washington, DC: The National Academies Press, 2012. Available at: http://www.iom.edu/Reports/2012/Monitoring-HIVCare-in-the-United-States.aspx. Accessed February 1, 2013.
40. Selik M, Mokotoff E, Branson B, et al. Revised Surveillance Case Definition for HIV Infection-United States, 2014. Atlanta, GA. MMWR. 2014;63(No. RR-3):1-10.
41. Nosyk B, Montaner JS, Colley G, et al. The cascade of HIV care in British Columbia, Canada, 1996-2011: a population-based retrospective cohort study. Lancet Infect Dis. 2014;14:40-49.
42. Mugavero MJ, Amico KR, Horn T, et al. The state of engagement in HIV care in the United States: from cascade to continuum to control. Clin Infect Dis. 2013;57:1164-1171.
43. National Quality Center. Guideline-based Quality Indicators for HIV Care. New York State Department of Health AIDS Institute Health Resources and Services Administration HIV/AIDS Bureau. New York, NY; 2008.
44. Lima VD, Harrigan R, Murray M, et al. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS. 2008;22:2371-2380.
45. Lima VD, Harrigan R, Bangsberg DR, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr. 2009;50:529-536.
46. Wood E, Hogg RS, Yip B, et al. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts ≥200 cells/microl. AIDS. 2006;20:1117-1123.
47. Lima VD, Le A, Nosyk B, et al. Development and validation of a composite programmatic assessment tool for HIV therapy. PLoS One. 2012;7:e47859.
48. Improvement IfH. The Breakthrough Series: IHI's Collaborative Model for Achieving Breakthrough Improvement. Boston, MA: Institute for Healthcare Improvement; 2003.
49. Horberg M, Hurley L, Towner W, et al. HIV Spectrum of Engagement Cascade in a Large Integrated Care System by Gender, Age, and Methodologies. 20th Conference on Retroviruses and Opportunisitc Infections, Atlanta 2013.
50. Cheng MP, Hirji A, Cook V, et al. Declining Rates of HIV-TB Co-infection in British Columbia and the Efficacy of Current Canadian Tuberculosis Screening Practices in the HAART Era. Paper presented at: Infectious Diseases; 2013; San Francisco, CA.
51. Forbes JC, Alimenti AM, Singer J, et al. A national review of vertical HIV transmission. AIDS. 2012;26:757-763.
52. Canada PHAo. At a Glance-HIV and AIDS in Canada: Surveillance Report. 2012. Available at: http://www.phac-aspc.gc.ca/aids-sida/publication/survreport/2012/dec/index-eng.php. Accessed March 10, 2014.
53. Ellis RP, Fiebig DG, Johar M, et al. Explaining health care expenditure variation: large-sample evidence using linked survey and health administrative data. Health Econ. 2013;22:1093-1110.
54. Doiron D, Raina P, Fortier I. Linking Canadian population health data: maximizing the potential of cohort and administrative data. Can J Public Health. 2013;104:e258-e261.
55. Jackson ML, Neuzil KM, Thompson WW, et al. The burden of community-acquired pneumonia in seniors: results of a populationbased study. Clin Infect Dis. 2004;39:1642-1650.
56. Christopoulos KA, Massey AD, Lopez AM, et al. Taking a half day at a time: patient perspectives and the HIV engagement in care continuum. AIDS Patient Care STDS. 2013;27:223-230.
57. Anthony MN, Gardner L, Marks G, et al. Factors associated with use of HIV primary care among persons recently diagnosed with HIV: examination of variables from the behavioural model of health-care utilization. AIDS Care. 2007;19:195-202.